D Winterling

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
We report results of a double-blind, 13-week trial of the alpha2 noradrenergic agonist guanfacine in 29 patients meeting clinical criteria for probable Alzheimer's disease (AD). Patients studied were relatively young (mean = 71 years), well educated (mean = 13.5 years), and in the early stages of cognitive deterioration (mean Mini-Mental State score = 22).(More)
  • 1